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Abstract
Background: Knowledge about signaling pathways in malignant cells may provide prognostic and diagnostic
information in addition to identify potential molecular targets for therapy. B-cell receptor (BCR) and co-receptor
CD40 signaling is essential for normal B cells, and there is increasing evidence that signaling via BCR and CD40
plays an important role in the pathogenesis of B-cell lymphoma. The aim of this study was to investigate basal and
induced signaling in lymphoma B cells and infiltrating T cells in single-cell suspensions of biopsies from small cell
lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and marginal zone lymphoma (MZL) patients.
Methods: Samples from untreated SLL/CLL and MZL patients were examined for basal and activation induced
signaling by phospho-specific flow cytometry. A panel of 9 stimulation conditions targeting B and T cells, including
crosslinking of the B cell receptor (BCR), CD40 ligand and interleukins in combination with 12 matching
phospho-protein readouts was used to study signaling.
Results: Malignant B cells from SLL/CLL patients had higher basal levels of phosphorylated (p)-SFKs, p-PLCγ, p-ERK,
p-p38, p-p65 (NF-κB), p-STAT5 and p-STAT6, compared to healthy donor B cells. In contrast, anti-BCR induced
signaling was highly impaired in SLL/CLL and MZL B cells as determined by low p-SFK, p-SYK and p-PLCγ levels.
Impaired anti-BCR-induced p-PLCγ was associated with reduced surface expression of IgM and CD79b. Similarly,
CD40L-induced p-ERK and p-p38 were also significantly reduced in lymphoma B cells, whereas p-p65 (NF-κB) was
equal to that of normal B cells. In contrast, IL-2, IL-7 and IL-15 induced p-STAT5 in tumor-infiltrating T cells were not
different from normal T cells.
Conclusions: BCR signaling and CD40L-induced p-p38 was suppressed in malignant B cells from SLL/CLL and MZL
patients. Single-cell phospho-specific flow cytometry for detection of basal as well as activation-induced
phosphorylation of signaling proteins in distinct cell populations can be used to identify aberrant signaling
pathways.
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Background
Small lymphocytic lymphoma/chronic lymphocytic
leukemia (SLL/CLL) and marginal zone lymphoma
(MZL) are indolent lymphoid malignancies that arise
from mature B cells. The exact cellular origin of SLL/CLL
is still controversial, although there is evidence that the
lymphoma arises from memory B cells [1]. By contrast,
splenic MZL possibly arises from naïve B cells whereas
nodal MZL cells are presumed to develop from normal
marginal zone B cells [2]. Therefore, signaling pathways
that are required for normal B cell maturation and func-
tion are likely disturbed in SLL/CLL and MZL. These sig-
naling pathways include the signals propagated through
the B-cell receptor (BCR), CD40 and cytokine receptors.
BCR is important for the proliferation, differentiation
and apoptosis of B cells [3]. Antigen stimulation via BCR
in normal B cells initiates phosphorylation of the immu-
noreceptor tyrosine-based activation motifs (ITAMs) in
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the cytoplasmic tails of CD79a and CD79b. Phosphoryl-
ation of ITAMs is mediated by different Src family
kinases (SFKs) including FYN, BLK, HCK, FGR, LCK
and LYN [4]. The phosphorylated ITAMs serve as dock-
ing sites for SYK which is then phosphorylated at con-
served tyrosine residues by SFKs. This activation
initiates the coordinate assembly of the signalosome,
composed of a variety of intracellular signaling mole-
cules and includes BTK, phosphatidylinositol 3-kinase
(PI3K), Vav and PLCγ. PLCγ activates PKC via DAG,
and this further phosphorylates downstream signaling
proteins like ERK, p38 and ultimately leads to activation
of the pleiotropic transcription factor NF-κB (p65) [5].
The balance of these signals determines the B-cell fate
[3]. There is now increasing evidence that signaling via
BCR plays an important role in the pathogenesis of CLL
[1]. However, there are conflicting results whether ex-
posure to anti-IgM in vitro promotes or suppresses
apoptosis in CLL cells [6] and other signals provided by
the tumor microenvironment likely determines the out-
come [7].
Activation of CD40, expressed by normal as well as
malignant B cells, is an important co-stimulatory signal
that enhances cell viability and promotes isotype class
switching [8]. Furthermore, activation of CD40 on B
cells induces expression of the co-stimulatory molecule
B7 (CD80), improves presentation of alloantigen [9], and
has been shown to activate NF-κB [10,11]. CD40-
induced signaling in CLL cells results in up-regulation of
NF-κB and activation of anti-apoptotic pathways [12-
14], and induces drug resistance [15]. CD40 stimulation
can also activate p38 in B-cell lymphoma cell lines [16].
Cytokine signaling in indolent B-cell lymphoma might
also be important for lymphomagenesis, since IL-2
stimulation of CLL cells down-regulates p27 and forces
the cells to traverse cell cycle [17]. However, conflicting
results have been reported regarding IL-2 production in
T cells from CLL patients [18,19].
Apart from providing information on potential mo-
lecular targets for therapy, the study of signaling
pathways may provide prognostic and diagnostic infor-
mation. Different properties of BCR signaling have been
identified in normal B cells and in lymphoma B cells
from follicular lymphoma patients [20,21], and impaired
BCR signaling identified a subset of follicular lymphoma
tumor cells with negative prognostic impact on patients
overall survival [22]. Therefore, measuring phospho-
proteins by flow cytometry to study signaling networks
in cancer cells as well as in infiltrating immune cells at
the single cell level [23,24] is feasible and relatively easy
to introduce into clinical practice.
The aim of this study was to use phospho-specific flow
cytometry to investigate basal and induced signaling in
lymphoma B cells and infiltrating T cells in single-cell
suspensions of biopsies from SLL/CLL and MZL
patients. The results were compared with those of per-
ipheral blood B cells and T cells from healthy donors
(PBMC). We used 9 different stimuli targeting B- and T
cells including CD40 ligand (CD40L), BCR engagement
by F(ab’)2 (anti-BCR), interleukin 2 (IL-2), IL-7, and IL-
15. The phospho-proteins studied included SFKs SYK,
PLCγ, AKT, S6, ERK, p38, STAT1, STAT3, STAT5,
STAT6 and NF-κB p65. Together, this yielded a compre-
hensive view of signaling networks in SLL/CLL and
MZL lymphoma B cells and in tumor-infiltrating T cells.
Methods
Patients and healthy donors
The study was approved by Regional Committee for
Medical Research Ethics (REK 2.2007.2949). Tumor bi-
opsies from previously untreated patients with SLL/CLL
(n = 11) and MZL (n = 5) were collected for diagnostic
purposes. Left-over samples were used for this study
after informed consent from the patients. Single-cell sus-
pensions were prepared from tumor biopsies and stored
in liquid nitrogen in cryotubes until used. All biopsies
were reviewed and subtyped according to the WHO
classification [25] by a hematopathologist.in 2010. Per-
ipheral blood was drawn from consenting healthy blood
donors (n=9) and PBMC were isolated by density gradi-
ent centrifugation (Lymphoprep Axis-Shield, Dundee,
United Kingdom). Cells were stored in liquid nitrogen in
cryotubes until used.
Reagents and Antibodies
Anti-BCR antibodies were a mixture of goat polyclonal
anti-human IgM F(ab’)2 and goat polyclonal anti-human
IgG F(ab’)2 (Invitrogen Carlsbad, CA, USA); each at a
final concentration of 10 μg/ml. H2O2 (Sigma-Aldrich,
Oslo, Norway) was used at a final concentration of 3.3
mM. The cells were stimulated with IL-2 at 500 U/ml,
IL-7 at 20 ng/ml, IL-15 at 20 ng/ml, and soluble CD40
ligand at 200 ng/ml (all from Peprotech, Rocky Hill, NJ,
USA). Phorbol 12-Myristate 13-Acetate (PMA) and
ionomycin (both from Sigma-Aldrich, Saint Louis,
Missouri, USA) were used at 1 μg/ml each.
Anti-CD20-PerCPCy5.5 (clone SK7), anti-CD5-PE-Cy7
(clone L17F12), anti-p-PLCγ2-Alexa488 (Y759), anti-p-
ERK1/2-Alexa488 (T202/Y204), anti-p-SYK / Zap70-
Alexa647 (Y352/Y319), anti-p-STAT1-Alexa488 (Y701),
anti-p-STAT6-Alexa647 (Y641), anti-p-p38-Alexa488
(T180/Y182), anti-p-STAT3-Alexa647 (Y705), anti-p-
LCK-Alexa488 (Y505), anti-p-STAT5-Alexa647 (Y694)
and anti-p-65(NF-κB)-Alexa488 (Ser529) were all from
BD Biosciences (San Jose, CA, USA). The antibodies
anti-p-S6-Alexa647 (Ser235/236) and anti-p-AKT-
Alexa647 (Ser473) were from Cell Signaling Technology
(Danvers, MA, USA). The following Abs were used for
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immune phenotypic analysis: CD3 PacBlue (UCHT1),
CD5 PE-Cy7 (L17F12), CD20 APC-H7 (L27), CD79a
APC (HM47), CD79b PE (SN8) and CD23 PerCPCY5.5
(M-L233) were from BD, and IgM FITC (AHI1608), IgG
FITC (AHI1308), IgL PE (AHI1907) and IgK APC
(MH10515) were from Invitrogen.
Activation of Signaling and Fluorescent cell barcoding
Individual cryotubes were thawed, cells were washed in
RPMI, counted and incubated for 30 minutes in a tissue
culture incubator at 37°C with 5% CO2. After this initial
incubation, 200 μl of the cell suspension was aliquoted
into a 96-well plate, and the cells were incubated an
additional 45 minutes at 37°C. Cells were then left un-
stimulated or activated with anti-BCR, H2O2, IL-2, IL-7,
IL-15, soluble CD40 ligand or with PMA and ionomycin
for 4, 15 or 45 minutes.
Signaling was stopped by fixation in paraformaldehyde
(Electron Microscopy Service, Hatfield, PA, USA) for 5
minutes at a final concentration of 1.5% at room
temperature. The cells were pelleted by high speed cen-
trifugation at 800 g, resuspended in PBS and permeabi-
lized in 90% methanol at −20°C for at least 10 minutes.
The cells where then pelleted by high speed centrifuga-
tion at 800 g and resuspended in PBS.
Fluorescent cell bar coding were then performed as
previously described [26]. Briefly, cells in each well
(=one stimulation condition) were stained with a unique
combination of two different fluorescent esters; Pacific
Blue and Pacific Orange (Invitrogen AS, Oslo, Norway),
each used at 3 different concentration level. This bar
coding made it possible to identify 3x3 different cell
populations (i.e. all the different stimulation conditions
given to one patient sample). Pacific Blue was used at a
final concentrations of 0.000780, 0.00702 or 0.0498, ng/
μL and Pacific Orange was used at 0.00870, 0.0870 or
0.522 ng/μL. Labeling was stopped by adding PBS w/ 1%
BSA and then pelleted by high speed centrifugation (800
g), resuspended in PBS with 1% BSA (Sigma-Aldrich,
Oslo, Norway) and combined in one tube per individual
patient sample.
Flow cytometry
The barcoded cells were aliquoted into six tubes for
staining with different antibody panels. Each panel con-
tained a backbone of the antibodies anti-CD20 and anti-
CD5 in addition to two different phospho-antibodies.
The cells were stained for 30 minutes in the dark at 4°C,
pelleted by centrifugation at 350 g and resuspended in
PBS.
For phenotypic analysis, freshly thawed patient sam-
ples were stained with various antibodies for 30 minutes
in the dark at 4°C, pelleted by centrifugation at 350 g
and resuspended in PBS. For staining with CD79a
(intracellular epitope), the cells were fixed and permea-
bilized using paraformaldehyde and 90% methanol as
described above, prior to Ab staining.
Acquisition was performed with a three-laser flow cyt-
ometer (FACSAria or LSR II, Becton Dickinson, Franklin
Lakes, NJ, USA). Data were collected and analyzed using
BD FACSDiva software and Cytobank Software (www.
Cytobank.org), respectively. Only data from samples of
which at least 50% of cells responded to any of the
stimulation condition were included.
Statistical analysis
GraphPad Software (La Jolla, CA, USA) was used to de-
termine statistical significance of difference between
groups by applying statistical tests as specified in results.
Cluster analysis
Hierarchical cluster analysis of flow cytometry data were
performed by the open source programs Cluster [27]
and Treeview [28] , with the use of complete linkage.
Results
Phospho-specific flow cytometry identifies different
signaling characteristics within cell subsets in lymphoma
biopsies
To examine whether intracellular signaling was
altered in samples from SLL/CLL and MZL patients,
we combined surface markers and phospho-protein
specific antibodies and detected basal as well as
activation-induced signaling by flow cytometry. Ma-
lignant B-cells were identified by their expression of
CD20 and CD5, and could be separated from CD20-
CD5+ infiltrating T cells. Crosslinking of BCR with
a mixture of anti-IgM and anti-IgG Abs (aBCR)
induced p-PLCγ only in B cells (Figure 1). Similarly,
CD40L induced p-p65 only in B cells (Figure 1). IL-7
induced p-STAT5 in T cells only, whereas PMA/iono-
mycin induced p-p65 in both cell types (Figure 1).
Together, these results show that signaling responses
can be studied in malignant B cells and distinguished
from those of infiltrating T cells.
Elevated basal levels of phospho-proteins in malignant B
cells from SLL/CLL patients
First, we asked whether there were differences in the
basal phospho-protein levels in malignant B cells from
SLL/CLL or MZL patients, relative to healthy donor B
cells. For this purpose, we analyzed samples from 11
SLL/CLL patients and 3 MZL patients where flow cyto-
metry data from healthy donor PBMCs, analyzed at the
same time, were available. The fold change in median
fluorescence intensity (MFI) for phospho-proteins in un-
stimulated malignant B cells from SLL/CLL or MZL
patients were normalized to the MFI in CD20+ B cells
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from peripheral blood B cells from healthy donors
(PBMC). We found significantly higher basal levels of
the following phospho-proteins in malignant B cells
from SLL/CLL patients: p-SFKs, p-PLCγ, p-ERK, p-p38
and p- p65 (NF-κB), p-STAT5 and p-STAT6 (Figure 2).
Of note, the basal levels of phospho-proteins were het-
erogeneous in patients samples as many of them showed
only small elevations (i.e. fold change <0.5), in contrast
to a few which had high basal levels (Figure 2). We also
observed higher levels of p-SYK in most SLL/CLL
patients, but this finding did not reach statistical signifi-
cance (p=0.068). Overall, we observed higher basal levels
of several phospho-proteins in malignant B cells from
SLL/CLL patients.
Impaired, but sustained BCR signaling in SLL/CLL and
MZL tumor B cells
Activation of BCR is important for survival and prolif-
eration of normal as well as malignant B cells. BCR acti-
vation of SLL/CLL cells can increase the level of the
anti-apoptotic protein MCL-1 and subsequent resistance
to fludarabine, or induce down-regulation of MCL-1 and
induction of apoptosis, depending on the nature of BCR
stimulation [29] . We therefore assessed phosphorylation
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Figure 1 Basal and activation induced signaling in samples from lymphoma patients and healthy donors. Samples from lymphoma
patients or from peripheral blood of healthy donors (PBMCs) were stimulated with various stimulation conditions (unstimulated, 4 minutes anti-(a)
BCR (crosslinking with anti-IgM/anti-IgG), or 15 minutes CD40L, IL-7 or PMA/ionomycin), followed by measurement of phospho-proteins using
flow cytometry. Contour plots show basal level (unstimulated) or activation-induced levels of p-PLCγ, p-p65 and p-STAT5, in a marginal
lymphoma patient sample (MZL-02) and a healthy donor PBMC (PBMC-02).
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Figure 2 Malignant B cells in SLL/CLL have higher basal levels of phospho-proteins. Scatter plots of the basal level of 8 phospho-proteins
in malignant B cells from SLL/CLL patients (SLL/CLL, n = 11), MZL patients (MZL, n = 3). Unstimulated samples were used for analysis of basal
level of phospho-proteins. MFI for each phospho-protein in the CD20+CD5+ (SLL/CLL) or CD20+ subset (MZL) were normalized to MFI in the
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0.05; Wilcoxon Signed Rank test.
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of several signaling proteins downstream of BCR, 4 and
45 minutes post BCR cross-linking, relative to unstimu-
lated B cells from the same individual. In normal B cells,
of the phospho-proteins analyzed, p-PLCγ showed the
largest increase after activation of BCR (Figure 3A).
Strikingly, BCR-induced phosphorylation of p-PLCγ was
significantly lower in the malignant B cells from SLL/
CLL and MZL patients, compared to healthy donor B
cells, with an 83% and 62% reduction in median MFI, re-
spectively. Importantly, phosphorylation of SYK/Zap70
and SFKs after 4 minutes of BCR stimulation was also
significantly impaired in SLL/CLL and MZL cells
(Figure 3A). Phosphorylation of SYK/Zap70 was reduced
by 85% and 56%, whereas phosphorylation of SFK was
reduced by 82% and 57% in SLL/CLL and MZL, respect-
ively. In comparison, there were only minor changes in
p-ERK after BCR stimulation in the lymphoma cells,
compared to normal B cells. Originally, CLL was
thought to be derived from CD5+ B cells [1].We tested if
CD5+CD20+ B cells from healthy donors also had sup-
pressed anti-BCR-induced signaling, compared to CD5-
CD20+ B cells. However, we found no difference in p-
SFKs, p-SYK, p-PLCγ and p-ERK expression at 4, 15 or
45 minutes of anti-BCR activation (Additional file 1:
Figure S1), suggesting that peripheral blood CD20+ B
cells serves as a relevant normal counterpart.
BCR signaling is controlled by protein tyrosine phos-
phatases (PTPs) that dephosphorylate signaling mole-
cules after activation in order to terminate signaling.
Hydrogen peroxide (H2O2) regulates the quantity and
length of signaling by inhibiting BCR-induced PTP activ-
ity [20]. When H2O2 was added immediately after BCR
cross-linking, BCR-induced signaling was restored in
lymphoma B cells, as BCR and H2O2-induced p-PLCγ,
p-SFKs and p-ERK were no longer significantly different
from healthy donor B cells (Figure 3A). Thus, these
results suggest that lymphoma B cells have impaired
BCR-induced signaling, but that inhibition of phospha-
tases can restore signaling in these cells. Furthermore, in
normal B cells, all investigated phospho-proteins except
p-S6, showed higher expression levels at 4 minutes com-
pared to 45 minutes after BCR activation (Figure 3B).
Delayed S6 phosphorylation with strongest activation 45
minutes after BCR cross-linking was also evident in
SLL/CLL and MZL cells. Normal B cells had a signifi-
cant decrease in levels of phosphorylated PLCγ, SYK,
SFKs and STAT5 from 4 to 45 minutes, in contrast to
SLL/CLL and MZL malignant B cells which showed no
significant decrease (Figure 3B). Thus, malignant B cells
from SLL/CLL and MZL had low, but sustained BCR-
induced signaling. Based on the observed results, a
model for BCR-induced signaling in lymphoma B cells
from SLL/CLL and MZL patients was constructed
(Figure 3C).
Low CD79b expression correlates with impaired BCR-
induced p-PLCγ
We next investigated if impaired BCR signaling in malig-
nant B cells from SLL/CLL or MZL patients could be
explained by loss or reduced cell surface levels of IgM,
CD79a or CD79b. A subgroup of SLL/CLL (n=6) and
MZL (n=4) patients were analyzed for this purpose
(Table 1). Expression of CD79b was frequently found to
be down-regulated in SLL/CLL and MZL patients, in
contrast to a more uniform expression of CD79a
(Figure 4A). Indeed, surface expression of CD79b
and IgM were greatly reduced in SLL/CLL (p=0.0013
and p=0.015, respectively), compared to healthy donor
CD20+ B cells (Figure 4B). Importantly, in malignant B
cells from SLL/CLL patients, BCR-induced p-PLCγ
was correlated with CD79b or IgM expression levels
(Figure 4C; r2=0.41 and r2=0.74, respectively). Altogether,
these results suggest that impaired BCR-induced signal-
ing in SLL/CLL lymphoma B cells is due to low surface
expression of IgM and CD79b.
Impaired CD40 signaling in SLL/CLL and MZL cells
In order to investigate CD40-induced signaling in malig-
nant B cells from SLL/CLL and MZL patients, phos-
phorylation of signaling proteins were assessed 15
minutes after CD40L stimulation. In healthy donor B
cells, CD40L induced the strongest increase in p-p65, p-
S6 and p-p38 (Figure 5). In contrast, malignant B cells
from SLL/CLL and MZL had significantly less CD40L-
induced p-p38 and p-ERK, compared to normal B cells.
Mean relative MFI levels of p-p38 in SLL/CLL and MZL
were 68% and 55% lower than in normal B cells, respect-
ively. Malignant B-cells from SLL/CLL also had impaired
CD40L-induced p-S6 (Figure 5). In contrast, no signifi-
cant difference was observed in CD40L-induced p-p65.
Altogether, CD40L signaling was clearly impaired in ma-
lignant B cells from SLL/CLL and MZL patients as a key
feature was diminished p38 phosphorylation.
Tumor-infiltrating T cells demonstrate similar interleukin-
induced STAT5 signaling as normal T cells
In order to assess whether signaling responses also
were altered in tumor-infiltrating T cells in SLL/CLL
and MZL, tumor samples were stimulated with IL-2,
IL-7 and IL-15 for 15 minutes and phospho-protein
levels were evaluated in the CD5+ CD20- T cell fraction
(Figure 6). In general, no significant differences in
cytokine-induced p-STAT5 were observed in tumor-
infiltrating T cells in SLL/CLL and MZL samples, com-
pared to T cells from healthy donors. It should be
noted that cytokine-induced signaling were markedly
heterogeneous in tumor-infiltrating T cells in the SLL/
CLL and MZL groups (Figure 6). Taken together,
tumor-infiltrating T cells in SLL/CLL samples displayed
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similar cytokine-signaling responses as compared to
healthy donor T cells.
Unsupervised cluster analysis of phospho-protein
expression profiles of SLL/CLL and MZL biopsies
compared to normal peripheral blood
We finally asked whether SLL/CLL and MZL could be
separated from healthy donors using unsupervised
cluster analysis, based on basal and activation-induced
phospho-protein levels. Unsupervised cluster analysis
revealed that samples from healthy donors clustered to-
gether, whereas samples from SLL/CLL and MZL made
several different clusters (Figure 7). One of the clusters
contained patient samples with higher basal levels of
several phospho-proteins, but had low cytokine-induced
p-STAT5 T-cell responses, whereas two other clusters
had low basal levels of phospho-proteins, but high
cytokine-induced p-STAT5 T cell responses. Whether
the different clusters identified can be translated into
meaningful clinical subclasses, will require similar ana-
lysis in a larger patient cohort.
Discussion
In this study we used phospho-specific flow cytometry
to map differences in signaling properties within the B-
and T-cell subsets from SLL/CLL and MZL patient sam-
ples. We found increased basal levels of several
phospho-proteins in lymphoma B cells, whereas they
overall had impaired, but sustained anti-BCR-induced p-
PLCγ, p-SYK/Zap70, p-SFKs and p-ERK, compared to
healthy donor B cells. Importantly, impaired BCR-
induced p-PLCγ was associated with reduced surface ex-
pression of IgM and CD79b. Additional signaling
aberrations in lymphoma B cells included CD40L-
induced p-p38 and p-ERK.
Overall, malignant B cells from SLL/CLL patients
showed significant higher basal levels of several phos-
pho-proteins, including p-SFKs, p-PLCγ, p-ERK, p-p38,
p-p65 (NF-κB), p-STAT5 and p-STAT6, but the levels
varied considerably between different patients. Constitu-
tive active STATs in SLL/CLL and MZL potentially have
biological significance, as targeting JAK/STAT pathways
had therapeutic benefits in relapsed lymphomas [30].
JAK2 inhibition by SB1518 prevented tyrosine phosphor-
ylation of STAT proteins, leading to cell cycle arrest and
induction of apoptosis [31]. Higher levels of basal p-ERK
and p-p38 in SLL/CLL lymphoma cells are also in agree-
ment with previous reports [32,33]. Earlier work with
primary CLL samples have shown constitutive phos-
phorylation of the SFK LYN, relative to normal B cells
[34] and constitutive phosphorylation of SYK relative to
cell lines [35,36]. We also observed higher basal levels of
p-SFKs, whereas basal p-SYK levels did not reach statis-
tical significance, possibly due to low number of
patients. The biological significance of basal p-SYK in
CLL has clinical relevance, since SLL/CLL patients trea-
ted with the SYK inhibitor R406 has shown promising
response rates [37]. Whether the lymphoma patients
whose lymphoma B cells’ have high basal levels of sig-
naling proteins such as p-SFK and p-SYK, also are the
ones with the greatest clinical responses upon specific
kinase inhibitor therapy, should be the focus of future
studies.
We found that BCR-induced p-SFK, p-SYK/p-Zap70,
p-PLCγ and p-ERK were highly impaired in SLL/CLL
and MZL lymphoma B cells, compared to normal B
cells. Furthermore, we found reduced levels of surface
IgM and CD79b in CLL/SLL lymphoma cells, and this
correlated with impaired anti-BCR-induced p-PLCγ.
Low expression of CD79b in CLL cells has also been
reported previously [38]. Furthermore, CLL tumor cells
which are unresponsive to anti-IgM, can respond to
anti-CD79a treatment, indicating a deficit in signal
transmission from the BCR to CD79a/b [36]. However,
since a subgroup of CLL samples was unresponsive to
(See figure on previous page.)
Figure 3 BCR induced signaling is impaired in SLL/CLL and MZL lymphoma B cells. Flow cytometry analysis of BCR-induced
phosphorylation of key signaling proteins downstream of BCR. Lymphoma patient samples and PBMCs from healthy donors were stimulated with
BCR crosslinking alone (anti-IgM/anti-IgG) or with a combination of BCR crosslinking and hydrogen peroxide (H2O2) for 4 or 45 minutes. (A)
Scatter plot showing relative MFI for each aBCR- or aBCR+H2O2-induced phospho-proteins in CD20
+ B cells after 4 minutes, normalized to the
MFI value in the corresponding unstimulated CD20+ B cells from the same individual. SLL/CLL (n = 11), MZL (n = 5) and PBMC (n = 9); * p < 0.05;
Mann Whitney test. (B) BCR induced phosphorylation after 4 and 45 minutes. Relative MFI was calculated as in A), and shown is bar charts of
mean relative MFI ± SEM, for SLL/CLL (n = 11); MZL (n = 5) and PBMC (n = 9). * p < 0.05; paired t test. (C) Overview of phosphorylated signaling
proteins after 4 minutes of BCR stimulation. Phospho-proteins investigated have red color. Pie charts indicate phospho-proteins with significant
reduced expression in SLL/CLL or MZL compared to normal B cells. The dark red color in pie charts indicates percentage of relative MFI in SLL/
CLL or MZL compared to normal B cells. Phospho-proteins with only light red color indicate no significant change of expression compared to
normal B cells.
Table 1 Immunophenotyping data in SLL/CLL and MZL
Lymphoma type Mean MFI relative to normal B cells (SEM)
IgM IgG CD79a CD79b
MZL 0.23 (0.62) −0.21 (0.28) 0.19 (0.33) −1.29 (0.43)
SLL/CLL −1.38 (0.38) −0.38 (0.24) −0.15 (0.18) −2.04 (0.32)
Expression of immunoglobulin and CD79 subclasses in SLL/CLL and MZL
compared to normal B cells presented as MFI fold change from normal B cells.
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activation with anti-CD79a, a potential defect further
downstream in the BCR signaling pathway is also pos-
sible [36]. Surface IgM expression varies considerably
among primary CLL samples, with a subset of patients
having markedly decreased IgM expression on the ma-
lignant cells [39-41]. Anti-IgM stimulation in primary
CLL samples results in global tyrosine phosphorylation
mainly in unmutated CLL, but not in mutated CLL
samples [36]. The differential response to BCR stimula-
tion in unmutated vs. mutated CLL has been confirmed
by other groups [42,43]. We did not find significant
different BCR-induced phosphorylation of target pro-
teins (SFKs, SYK, PLCγ, ERK and STAT5) between
unmutated and mutated SLL/CLL, possibly due to
small sample size (data not shown). Further, ZAP-70
expression can enhance BCR signaling after anti-IgM
treatment, independent of its kinase activity [44], and
CLL cells that expressed ZAP-70 had significantly
higher levels of phosphorylated CD79b compared to
CLL lacking ZAP-70.
CD40L-induced signaling was also impaired in SLL/
CLL and MZL lymphoma B cells compared to normal B
cells with significant lower phosphorylation of p38, ERK
and S6 in SLL/CLL and lower p38 and ERK in MZL.
This finding is in line with previous observations were
CD40L stimulation resulted in diminished protein tyro-
sine kinase phosphorylation in CLL B cells compared to
normal B cells, despite similar expression levels of CD40
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Figure 4 Low CD79b and IgM expression in SLL/CLL cells correlates with impaired aBCR-induced p-PLCγ. (A) Contour plot showing CD20
and CD79b expression in CD20+ B cells from representative normal PBMC, MZL (n=2) and SLL/CLL (n=4). (B) Bar chart illustrating expression of
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[45]. The reason for diminished p-p38 expression in
SLL/CLL and MZL lymphoma B cells is unclear. Activa-
tion of p38 has a pro-apoptotic function in CLL cells,
and earlier work has shown that rituximab-induced
apoptosis is dependent on phosphorylation of p38 [46].
Furthermore, recent work in primary CLL cells illus-
trates that chemotherapy-induced up-regulation of the
pro-apoptotic protein NOXA is at least partly dependent
on p38 [47]. Thus, loss of p38 function is likely to give
the tumor cells a survival advantage. Therefore, the role
of p-p38 in B-cell malignancies warrants further investi-
gation. In contrast to the overall weak CD40L induced
phosphorylation of p38 in malignant B cells, p-p65 (NF-
κB) expression was markedly heterogeneous in SLL/CLL
and MZL. This finding is in accordance with earlier
work where lymphoma B cells from CLL patients were
heterogeneous in basal- as well as activation-induced
NF-κB [48]. This has potentially clinical implications as
a correlation between the NF-κB subunit Rel-A (p65)
DNA binding in CLL cells and lymphocyte doubling
time was identified, and Rel-A DNA binding
was positively correlated with in vitro resistance to
fludarabine [48].
CD40 stimulation resulted in strong phosphorylation
of S6 in MZL cells, in a subset of SLL/CLL samples, and
in normal B cells. Interestingly, induction of p-S6
seemed to be partially independent of PI3K since we did
not find an increased p-AKT level after stimulation with
CD40L. Similarly, in SLL/CLL B-lymphoma cells BCR
activation resulted in high levels of p-S6, with only small
increase in p-AKT. PI3K-independent activation of
mTor has previously been described in transformed B
cells [49]. Furthermore, it was previously shown that
marginal zone B cells expressed more PI3K independent
p-S6 after BCR stimulation than follicular B cells [50].
Inhibition of mTor is a potential target in cancer ther-
apy, and clinical trials with its inhibitor everolimus have
shown promising results in CLL [51]. Thus, the marked,
but variable levels of p-S6 in both unstimulated (data
not shown) and CD40L activated cells suggests that de-
tection of p-S6 could be tested as a biomarker in clinical
trials with mTor inhibitors.
Tumor-infiltrating T cells in SLL/CLL and MZL
showed no significant differences in cytokine induced
STAT5 phosphorylation, compared to normal T cells.
This was in contrast to ligand independent stimulation
which resulted in decreased phosphorylation of p38 and
NF-κB p65 in the former. Earlier work with tumor-
infiltrating T cells from CLL patients demonstrates de-
fective immunological synapse formation with antigen
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presenting cells together with reduced tyrosine-
phosphorylated proteins at the synapse [52]. Of interest,
we found a marked variability in cytokine-induced sig-
naling between SLL/CLL and MZL cell samples.
Whether this has prognostic significance for these dis-
eases, remains to be demonstrated.
Conclusions
In conclusion, this work has provided a better overview
of basal, BCR- and CD40L-induced signaling in lymph-
oma B cells as well as cytokine-induced signaling
responses in infiltrating T cells in patients with SLL/CLL
and MZL. Although we did not identify unique signaling
profiles that could distinguish SLL/CLL from MZL, we
identified contrasting signaling abnormalities in the
lymphoma B cells compared to normal B cells. Further
studies using single-cell phospho-specific flow cytometry
to obtain patient specific signaling aberrations could
provide an opportunity to personalize inhibitor treat-
ment in B cell lymphoma patients.
Additional file
Additional file 1: Figure S1. No difference in anti-BCR induced
signaling between CD20+CD5- and CD20+CD5+ B cells. PBMCs (n=4)
from healthy donors were stimulated with aBCR for 4, 15 or 45 minutes.
Flow cytometry analysis of p-SFKs, p-SYK, p- PLCγ and p-S6 after gating
on CD20+CD5+ or CD20+CD5- cells. (A) MFI in aBCR stimulated cells
relative to unstimulated cells from the same subset is illustrated as
heatmap. (B) Bar charts with median relative MFI ± SEM, n=4 healthy
donors.
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